Related Experiment Video
Updated: Sep 4, 2025

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
Clinical and pathological investigation of oligomeganephronia
Hideaki Kitakado1, Tomoko Horinouchi2, Chika Masuda1
1Department of Pediatrics, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Background:
Oligomeganephronia (OMN) is a rare congenital anomaly involving the kidney and urinary tract, characterized by decreased number and compensatory hypertrophy of the nephron. It is caused by abnormal kidney development during the embryonic period, especially in patients with low birth weight; however, the actual etiology and clinical features remain unknown. We aim to reveal the clinical and pathological characteristics, treatment, and outcome.
Methods:
Ten patients diagnosed with OMN between 2013 and 2020 were retrospectively investigated. The data were presented as the median ± interquartile range, and statistical significance was set at p < 0.05.
Results:
The age at diagnosis was 14.1 years, the male-to-female ratio was 6:4, and only four cases were born with low birth weight. The estimated glomerular filtration rate (eGFR) was 62.2 mL/min/1.73 m2. The glomerulus diameter of OMN patients was significantly larger (217 vs. 154 µm, p < 0.001) in OMN patients, and the number of glomeruli of OMN patients was lower (0.89 vs. 2.05/mm2, p < 0.001) than the control group. Eight of the ten cases were identified by urinary screening. Nine patients were treated with renin-angiotensin system (RAS) inhibitors, following which proteinuria successfully decreased or disappeared. Their median eGFR was also stable, 53.3 mL/min/1.73 m2.
Conclusions:
As few symptoms can lead to OMN discovery, most patients were found during urine screening at school. Kidney dysfunction was observed in all patients at the time of kidney biopsy. Proteinuria has been significantly reduced and the decline rate of eGFR might be improved by RAS inhibitors. "A higher resolution version of the Graphical abstract is available as Supplementary information".
Insights
Oligomeganephronia (OMN) is a rare kidney anomaly characterized by fewer, larger nephrons. Early detection through urine screening and treatment with renin-angiotensin system inhibitors can manage proteinuria and stabilize kidney function.
Area of Science:
- Nephrology
- Pediatric Nephrology
- Congenital Kidney Disorders
Background:
- Oligomeganephronia (OMN) is a rare congenital kidney anomaly with reduced nephron number and compensatory hypertrophy.
- Etiology and clinical features are not well understood, though abnormal embryonic kidney development is implicated, particularly in low birth weight infants.
Purpose of the Study:
- To elucidate the clinical and pathological characteristics of Oligomeganephronia.
- To investigate treatment strategies and patient outcomes for OMN.
Main Methods:
- Retrospective analysis of ten patients diagnosed with OMN between 2013 and 2020.
- Data presented as median ± interquartile range; statistical significance set at p < 0.05.
Main Results:
- Patients diagnosed at a median age of 14.1 years (6:4 male:female ratio); only 4/10 had low birth weight.
- OMN kidneys showed significantly larger glomeruli (217 vs. 154 µm) and fewer glomeruli per area (0.89 vs. 2.05/mm²).
- Eight cases detected via urinary screening; renin-angiotensin system inhibitors reduced proteinuria in nine patients, stabilizing eGFR.
Conclusions:
- OMN often presents with subtle symptoms, leading to discovery via school urine screenings.
- Kidney dysfunction is present at diagnosis; renin-angiotensin system inhibitors show promise in reducing proteinuria and potentially slowing eGFR decline.
More Related Videos
08:33Olfactory Neurons Obtained through Nasal Biopsy Combined with Laser-Capture Microdissection: A Potential Approach to Study Treatment Response in Mental Disorders
Published on: December 4, 2014
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Related Concept Videos
Hypertension III: Clinical Manifestations and Diagnostic Studies
Nephrotic Syndrome II : Assessment and Medical Management
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease II: Clinical Manifestations
Nephrotic Syndrome I : Introduction
Nephrons